OmniAb signs agreement for antibody discovery with new incubated company

OmniAb (OABI) signied a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG, a joint venture between ArrowMark and Viking Global Investors. OmniAb will receive revenue for services performed as well as potential equity and royalties for the discovery of novel antibodies for targets defined by Mabtrx. ArrowMark Partners is a privately held, employee-owned investment management firm founded in 2007 and headquartered in Denver, Colorado. Founded in 1999, Viking Global Investors is a global investment firm with a long-term, fundamental, research-intensive approach to investing. Viking manages over $55B of capital across public and private investments.